Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

British Journal of Haematology

Volumn 128, Issue 3, 2005, Pages 275-290

  Elliott, Michelle A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Essential thrombocythaemia; Haemorrhage; Polycythaemia vera; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; HYDROXYUREA; TICLOPIDINE; VON WILLEBRAND FACTOR;

AGE; ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; BONE MARROW SUPPRESSION; CARDIOTOXICITY; DEPRESSION; DIARRHEA; EDEMA; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKEMIA; LEUKOCYTE; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUTROPENIA; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN ULCER; TERATOGENICITY; THROMBOCYTHEMIA; THROMBOSIS; THYROID DISEASE;

AGED; ASPIRIN; HEMORRHAGE; HUMANS; HYDROXYUREA; MIDDLE AGED; POLYCYTHEMIA VERA; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 13444256042     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05277.x     Document Type: Review

References (152)

1. Adami, R. (1993) Therapeutic thrombocytapheresis: a review of 132 patients. International Journal of Artificial Organs, 16(Suppl. 5), 183-184.
2. Afshar-Kharghan, V.L.A., Gray, L., Padilla, A., Borthakur, G., Roberts, S., Pruthi, R. & Tefferi, A. (2001) Hemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia. Blood, 98, 471a.
3. Amitrano, L., Guardascione, M.A., Ames, P.R., Margaglione, M., Antinolfi, I., Iannaccone, L., Annunziata, M., Ferrara, F., Brancaccio, V. & Balzano, A. (2003) Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. American Journal of Hematology, 72, 75-81.
4. Anger, B., Haug, U., Seidler, R. & Heimpel, H. (1989a) Polycythemia vera. A clinical study of 141 patients. Blut, 59, 493-500.
5. Anger, B.R., Seifried, E., Scheppach, J. & Heimpel, H. (1989b) Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klinische Wochenschrift, 67, 818-825.
6. Antithrombotic Trialist's Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 71-86.
7. Asano, Y. & Okaniwa, A. (1987) In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats. Jikken Dobutsu, 36, 143-149.
8. Baker, R.I. & Manoharan, A. (1988) Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. European Journal of Haematology, 40, 267-272.
9. Balduini, C.L., Bertolino, G., Noris, P. & Piletta, G.G. (1991) Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. American Journal of Clinical Pathology, 95, 82-86.
10. Barbui, T. & Finazzi, G. (2003) Indications for cytoreductive therapy in polycythemia vera and essential thrombocythemia. Hematology, 2003, 202-209.
11. Barbui, T., Cortelazzo, S., Viero, P., Bassan, R., Dini, E. & Semeraro, N. (1983) Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. European Journal of Cancer and Clinical Oncology, 19, 1593-1599.
12. Barbui, T., Barosi, G., Grossi, A., Gugliotta, L., Liberato, L.N., Marchetti, M., Mazzucconi, M.G., Rodeghiero, F. & Tura, S. (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Experimental Hematology. Haematologica, 89, 215-232.
13. Barton, J., Lavker, R.M., Schechter, N.M. & Lazarus, G.S. (1985) Treatment of urticaria pigmentosa with corticosteroids. Archives of Dermatology, 121, 1516-1523.
14. Bazzan, M., Tamponi, G., Schinco, P., Vaccarino, A., Foli, C., Gallone, G. & Pileri, A. (1999) Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Annals of Hematology, 78, 539-543.
15. Beck, Jr M.R., & Eckstein, E.G. (1980) Preliminary report on platelet concentration in capillary tube flows of whole blood. Biorheology, 17, 455-464.
16. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. & Boiron, M. (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer, 58, 2440-2447.
17. Berk, P.D., Goldberg, J.D., Silverstein, M.N., Weinfeld, A., Donovan, P.B., Ellis, J.T., Landaw, S.A., Laszlo, J., Najean, Y., Pisciotta, A.V. & Wasserman, L.R. (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. New England Journal of Medicine, 304, 441-447.
18. Berk, P.D., Goldberg, J.D., Donovan, P.B., Fruchtman, S.M., Berlin, N.I. & Wasserman, L.R. (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23, 132-143.
19. Besses, C., Cervantes, F., Pereira, A., Florensa, L., Sole, F., Hernandez-Boluda, J.C., Woessner, S., Sans-Sabrafen, J., Rozman, C. & Montserrat, E. (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia, 13, 150-154.
20. Bond, L. & Bevan, D. (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. New England Journal of medicine, 318, 121.
21. Brodmann, S., Passweg, J.R., Gratwohl, A., Tichelli, A. & Skoda, R.C. (2000) Myeloproliferative disorders: complications, survival and causes of death. Annals of Hematology, 79, 312-318.
22. Budde, U. & van Genderen, P.J. (1997) Acquired von Willebrand disease in patients with high platelet counts. Seminars in Thrombosis and Hemostasis, 23, 425-431.
23. Budde, U., Schaefer, G., Mueller, N., Egli, H., Dent, J., Ruggeri, Z. & Zimmerman, T. (1984) Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood, 64, 981-985.
24. Budde, U., Dent, J.A., Berkowitz, S.D., Ruggeri, Z.M. & Zimmerman, T.S. (1986) Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood, 68, 1213-1217.
25. Budde, U., Scharf, R.E., Franke, P., Hartmann-Budde, K., Dent, J. & Ruggeri, Z.M. (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood, 82, 1749-1757.
26. Burstein, S.A., Malpass, T.W., Yee, E., Kadin, M., Brigden, M., Adamson, J.W. & Harker, L.A. (1984) Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. British Journal of Haematology, 57, 383-392.
27. Buss, D.H., Stuart, J.J. & Lipscomb, G.E. (1985) The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. American Journal of Hematology, 20, 365-372.
28. Byrnes, J.J., Larcada, A. & Moake, J.L. (1988) Thrombosis following desmopressin for uremic bleeding. American Journal of Hematology, 28, 63-65.
29. Cardin, F., Graffeo, M., McCormick, P.A., McIntyre, N. & Burroughs, A. (1992) Adult "idiopathic" extrahepatic venous thrombosis. Importance of putative "latent" myeloproliferative disorders and comparison with cases with known etiology. Digestive Diseases and Sciences, 37, 335-339.
30. Chiusolo, P., La Barbera, E.O., Laurenti, L., Piccirillo, N., Sora, F., Giordano, G., Urbano, R., Mazzucconi, M.G., De Stefano, V., Leone, G. & Sica, S. (2001) Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Experimental Hematology, 29, 670-676.
31. Colombi, M., Radaelli, F., Zocchi, L. & Maiolo, A.T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer, 67, 2926-2930.
32. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. & Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology, 8, 556-562.
33. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine, 332, 1132-1136.
34. Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. Blood, 6, 372-375.
35. Denninger, M.H., Chait, Y., Casadevall, N., Hillaire, S., Guillin, M.C., Bezeaud, A., Erlinger, S., Briere, J. & Valla, D. (2000) Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology, 31, 587-591.
36. Dicato, M.A., Schroell, B. & Berchem, G.J. (1999) V Leiden mutations, prothromin and methylene-tetrahydrofolate reductase are not risk factors for thromboembolic disease in essential thrombocythemia. Blood, 94, 111a
37. Doll, D.C., Ringenberg, Q.S. & Yarbro, J.W. (1989) Antineoplastic agents and pregnancy. Seminars in Oncology, 16, 337-346.
38. Elliott, M.A. & Tefferi, A. (1997) Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Seminars in Thrombosis and Hemostasis, 23, 463-472.
39. Elliott, M.A. & Tefferi, A. (2003) Thrombocythaemia and pregnancy. Bailliere's Best Practice in Clinical Haematology, 16, 227-242.
40. Falanga, A., Marchetti, M., Evangelista, V., Vignoli, A., Licini, M., Balicco, M., Manarini, S., Finazzi, G., Cerletti, C. & Barbui, T. (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 96, 4261-4266.
41. Faurschou, M., Nielsen, O.J., Jensen, M.K. & Hasselbalch, H.C. (2000) High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. American Journal of Hematology, 65, 136-140.
42. Favaloro, E.J. (2000) Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thrombosis and Haemostasis, 83, 127-135.
43. Fenaux, P., Simon, M., Caulier, M.T., Lai, J.L., Goudemand, J. & Bauters, F. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer, 66, 549-556.
44. Fey, M.F. (1985) Spontaneous massive abdominal wall hematoma in polycythemia vera. Acta Haematologica, 73, 122-123.
45. Finazzi, G., Ruggeri, M., Rodeghiero, F. & Barbui, T. (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. [see comment]. British Journal of Haematology, 110, 577-583.
46. Furlan, M., Robles, R. & Lamie, B. (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 87, 4223-4234.
47. Galli, M., Luciani, D., Bertolini, G. & Barbui, T. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 101, 1827-1832.
48. van Genderen, P.J. & Leenknegt, H. (1999) Normal binding of plasma von Willebrand factor to platelets in essential thrombocythemia. American Journal of Hematology, 61, 153-154.
49. van Genderen, P.J. & Michiels, J.J. (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Medicale, 23, 73-77.
50. van Genderen, P.J., Michiels, J.J., van der Poel-van de Luytgaar de, S.C. & van Vliet, H.H. (1994) Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Annals in Hematology, 69, 81-84.
51. van Genderen, P.J., Michiels, J.J., van Strik, R., Lindemans, J. & van Vliet, H.H. (1995) Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thrombosis and Haemostasis, 73, 210-214.
52. van Genderen, P.J., Lucas, I.S., van Strik, R., Vuzevski, V.D., Prins, F.J., van Vliet, H.H. & Michiels, J.J. (1996a) Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thrombosis and Haemostasis, 76, 333-338.
53. van Genderen, P.J., Budde, U., Michiels, J.J., van Strik, R. & van Vliet, H.H. (1996b) The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. British Journal of Haematology, 93, 962-965.
54. van Genderen, P.J., Leenknegt, H. & Michiels, J.J. (1997a) The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link? Seminars in Thrombosis and Hemostasis, 23, 385-389.
55. van Genderen, P.J., Prins, F.J., Lucas, I.S., van de Moesdijk, D., van Vliet, H.H., van Strik, R. & Michiels, J.J. (1997b) Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. British Journal of Haematology, 99, 832-836.
56. van Genderen, P.J., van Vliet, H.H., Prins, F.J., de Moesdijk, D., van Strik, R., Zijlstra, F.J., Budde, U. & Michiels, J.J. (1997c) Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Annals of Hematology, 75, 215-220.
57. van Genderen, P.J., Mulder, P.G., Waleboer, M., van de Moesdijk, D. & Michiels, J.J. (1997d) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. British Journal of Haematology, 97, 179-184.
58. Gersuk, G.M., Carmel, R. & Pattengale, P.K. (1989) Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood, 74, 2330-2334.
59. Gisslinger, H., Rodeghiero, F., Ruggeri, M., Heis-Vahidi Fard, N., Mannhalter, C., Papagiannopoulos, M., Rintelen, C., Lalouschek, W., Knobl, P., Lechner, K. & Pabinger, I. (1999) Homocysteine levels in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 105, 551-555.
60. Greist, A. (2002) The role of blood component removal in essential and reactive thrombocytosis. Therapeutic Apheresis, 6, 36-44.
61. Grima, K.M. (2000) Therapeutic apheresis in hematological and oncological diseases. Journal of Clinical Apheresis, 15, 28-52.
62. Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Annals of Internal Medicine, 123, 656-664.
63. Harrison, C.N., Gale, R.E., Machin, S.J. & Linch, D.C. (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417-424.
64. Harrison, C.N., Donohoe, S., Carr, P., Dave, M., Mackie, I. & Machin, S.J. (2002) Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thrombosis and Haemostasis, 87, 802-807.
65. Huang, P.Y. & Hellums, J.D. (1993) Aggregation and disaggregation kinetics of human blood platelets: Part III. The disaggregation under shear stress of platelet aggregates. Biophysical Journal, 65, 354-361.
66. Ishihara, S., Yasuhara, H., Ogawa, S. & Muto, T. (2000) Successful surgical treatment for spontaneous retroperitoneal hematoma in polycythemia vera: report of a case. Surgery Today, 30, 199-201.
67. Jacobson, A.K. (2004) Platelet ADP receptor antagonists: ticlopidine and dopidogrel. Best Practical Research in Clinical Haematology, 17, 55-64.
68. Jantunen, R., Juvonen, E., Ikkala, E., Oksanen, K., Anttila, P. & Ruutu, T. (2001) The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Annals of Hematology, 80, 74-78.
69. Jensen, M.K., de Nully Brown, P., Nielsen, O.J. & Hasselbalch, H.C. (2000a) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. European Journal of Haematology, 65, 132-139.
70. Jensen, M.K., de Nully Brown, P., Lund, B.V., Nielsen, O.J. & Hasselbalch, H.C. (2000b) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. British Journal of Haematology, 110, 116-124.
71. Jensen, M.K., de Nully Brown, P., Lund, B.V., Nielsen, O.J. & Hasselbalch, H.C. (2001) Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. European Journal of Haematology, 66, 143-151.
72. Jensen, M.K., de Nully Brown, P., Thorsen, S. & Hasselbalch, H.C. (2002) Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. American Journal of Hematology, 69, 185-191.
73. Juvonen, E., Partanen, S. & Ruutu, T. (1987) Colony formation by megakaryocytic progenitors in essential thrombocythaemia. British Journal of Haematology, 66, 161-164.
74. Kaplan, M.E., Mack, K., Goldberg, J.D., Donovan, P.B., Berk, P.D. & Wasserman, L.R. (1986) Long-term management of polycythemia vera with hydroxyurea: a progress report. Seminars in Hematology, 23, 167-171.
75. el-Kassar, N., Hetet, G., Briere, J. & Grandchamp, B. (1997) Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood, 89, 128-134.
76. Kassum, D. & Thomas, E.J. (1977) Morbidity and mortality of incidental splenectomy. Canadian Journal of Surgery, 20, 209-214.
77. Kaywin, P., McDonough, M., Insel, P.A. & Shattil, S.J. (1978) Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. New England Journal of Medicine, 299, 505-509.
78. Kessler, C.M., Klein, H.G. & Havlik, R.J. (1982) Uncontrolled thrombocytosis in chronic myeloproliferative disorders. British Journal of Haematology, 50, 157-167.
79. Key, N.S. & McGlennen, R.C. (2002) Hyperhomocyst(e)inemia and Thrombophilia. Archives of Pathology and Laboratory Medicine, 126, 1367-1375.
80. Landolfi, R. & Marchioli, R. (1997) European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Seminars in Thrombosis and Hemostasis, 23, 473-478.
81. Landolfi, R., Ciabattoni, G., Patrignani, P., Castellana, M.A., Pogliani, E., Bizzi, B. & Patrono, C. (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. [see comment]. Blood, 80, 1965-1971.
82. Landolfi, R., Rocca, B. & Patrono, C. (1995) Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Critical Reviews in Oncology-Hematology, 20, 203-222.
83. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., Barbui, T. & European Collaboration on Low-Dose Aspirin in Polycythemia Vera, I. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114-124.
84. Le Blanc, K., Lindahl, T., Rosendahl, K. & Samuelsson, J. (1998) Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thrombosis Research, 91, 287-295.
85. Lengfelder, E., Hochhaus, A., Kronawitter, U., Hoche, D., Queisser, W., Jahn-Eder, M., Burkhardt, R., Reiter, A., Ansari, H. & Hehlmann, R. (1998) Should a platelet limit of 600 x 10(9)/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. British Journal of Haematology, 100, 15-23.
86. Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, Jr J.D., Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488-494.
87. Lopez-Fernandez, M.F., Lopez-Berges, C., Martin, R., Pardo, A., Ramos, F.J. & Batlle, J. (1987) Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thrombosis and Haemostasis, 58, 753-757.
88. Malmaeus, J., Akre, T., Adami, H.O. & Hagberg, H. (1986). Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. British Journal of Surgery, 73, 720-723.
89. Mazzucato, M., De Marco, L., De Angelis, V., De Roia, D., Bizzaro, N. & Casonato, A. (1989) Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. British Journal of Haematology, 73, 369-374.
90. Melear, J.M., Goldstein, R.M., Levy, M.F., Molmenti, E.P., Cooper, B., Netto, G.J., Klintmalm, G.B. & Stone, M.J. (2002) Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation, 74, 1090-1095.
91. Menon, K.V., Shah, V. & Kamath, P.S. (2004) The Budd-Chiari syndrome, [see comment]. New England Journal of Medicine, 350, 578-585.
92. Michiels, J.J. (1997) Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism-thesis, Rotterdam, 1981. Seminars in Thrombosis Hemostasis, 23, 335-338.
93. Michiels, J.J., Abels, J., Steketee, J., van Vliet, H.H. & Vuzevski, V.D. (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Annals of Internal Medicine, 102, 466-471.
94. Michiels, J.J., Koudstaal, P.J., Mulder, A.H. & van Vliet, H.H. (1993) Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology, 43, 1107-1110.
95. Michiels, J.J., van Genderen, P.J., Jansen, P.H. & Koudstaal, P.J. (1996) Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leukemia and Lymphoma, 22 (Suppl. 1), 65-70.
96. Michiels, J.J., Budde, U., van der Planken, M., van Vliet, H.H., Schroyens, W. & Berneman, Z. (2001) Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Bailliere's Best Practice in Clinical Haematology, 14, 401-136.
97. Najean, Y., Mugnier, P., Dresch, C. & Rain, J.D. (1987) Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. British Journal of Haematology, 67, 285-291.
98. Passamonti, F. (2004) The natural history of PV and ET. American Journal of Medicine (in press).
99. Passamonti, F., Malabarba, L., Orlandi, E., Pascutto, C., Brusamolino, E., Astori, C., Barate, C., Canevari, A., Corso, A., Bernasconi, P., Cazzola, M. & Lazzarino, M. (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. British Journal of Haematology, 116, 855-861.
100. Passamonti, F., Malabarba, L., Orlandi, E., Barate, C., Canevari, A., Brusamolino, E., Bonfichi, M., Arcaini, L., Caberlon, S., Pascutto, C. & Lazzarino, M. (2003) Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. [comment]. Haematologica, 88, 13-18.
101. Patrono, C., Coller, B., Dalen, J.E., FitzGerald, G.A., Fuster, V., Gent, M., Hirsh, J. & Roth, G. (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest, 119, 39S-63S.
102. Pearson, T.C. (1997) Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Seminars in Thrombosis and Hemostasis, 23, 433-139.
103. Pearson, T.C. (2002) The risk of thrombosis in essential thrombocythemia and polycythemia vera. Seminars in Oncology, 29, 16-21.
104. Pearson, T.C. & Wetherley-Mein, G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 2, 1219-1222.
105. Perea, G., Remacha, A., Besses, C., Jimenez, M., Florensa, L. & Cervantes, F. (2001) Is polycythemia vera a serious disease in young adults? Haematologica, 86, 543-544.
106. Petitt, R.M., Silverstein, M.N. & Petrone, M.E. (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Seminars in Hematology, 34, 51-54.
107. Press, R.D., Bauer, K.A., Kujovich, J.L. & Heit, J.A. (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Archives of Pathology and Laboratory Medicine, 126, 1304-1318.
108. Randi, M.L., Stocco, F., Rossi, C., Tison, T. & Girolami, A. (1991) Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). Journal of Medicine, 22, 213-223.
109. Randi, M.L., Rossi, C., Fabris, F., Menapace, L. & Girolami, A. (1999a) Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clinical Applications in Thrombosis and Hemostasis, 5, 131-135.
110. Randi, M.L., Luzzatto, G. & Fabris, F. (1999b) Low-risk essential thrombocythaemia in patients younger than 40[comment]. British Journal of Haematology, 104, 929.
111. Randi, M.L., Fabris, F., Ruzzon, E., Pacquola, E., Cella, G. & Girolami, A. (2002). Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Haematologica, 87, 1180-1184.
112. Regev, A., Stark, P., Blickstein, D. & Lahav, M. (1997) Thrombotic complications in essential thrombocythemia with relatively low platelet counts. American Journal of Hematology, 56, 168-172.
113. Remaley, A.T., Kennedy, J.M. & Laposata, M. (1989) Evaluation of the clinical utility of platelet aggregation studies. American Journal of Hematology, 31, 188-193.
114. Rocca, B., Ciabattoni, G., Tartaglione, R., Cortelazzo, S., Barbui, T., Patrono, C. & Landolfi, R. (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thrombosis Haemostasis, 74, 1225-1230.
115. Rosendaal, F.R. (1997) Risk factors for venous thrombosis: prevalence, risk, and interaction. Seminars in Hematology, 34, 171-187.
116. Rozman, C., Giralt, M., Feliu, E., Rubio, D. & Cortes, M.T. (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 67, 2658-2663.
117. Ruggeri, Z.M. (2001) Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Practical Research in Clinical Haematology, 14, 257-279.
118. Ruggeri, M., Castaman, G. & Rodeghiero, F. (1993) Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica, 78, 18-21.
119. Ruggeri, M., Finazzi, G., Tosetto, A., Riva, S., Rodeghiero, F. & Barbui, T. (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. British Journal of Haematology, 103, 772-777.
120. Ruggeri, M., Gisslinger, H., Tosetto, A., Rintelen, C., Mannhalter, C., Pabinger, I., Heis, N., Castaman, G., Missiaglia, E., Lechner, K. & Rodeghiero, F. (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 71, 1-6.
121. Sadler, J.E., Mannucci, P.M., Berntorp, E., Bochkov, N., Boulyjenkov, V., Ginsburg, D., Meyer, D., Peake, I., Rodeghiero, F. & Srivastava, A. (2000) Impact, diagnosis and treatment of von Willebrand disease. Thrombosis and Haemostasis, 84, 160-174.
122. Sato, K. (1988) Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia. Keio Journal of Medicine, 37, 54-71.
123. Schafer, A.I. (1982) Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. New England Journal of Medicine, 306, 381-386.
124. Schafer, A.I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64, 1-12.
125. Shih, L.Y., Lin, T.L., Lai, C.L., Dunn, P., Wu, J.H., Wang, P.N., Kuo, M.C. & Lee, L.C. (2002) Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood, 100, 1596-1601.
126. Solberg, Jr L.A., Tefferi, A., Oles, K.J., Tarach, J.S., Petitt, R.M., Forstrom, L.A. & Silverstein, M.N. (1997) The effects of anagrelide on human megakaryocytopoiesis. British Journal of Haematology, 99, 174-180.
127. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia:risks and benefits up to 9 years of treatment. [see comment] [erratum appears in JAMA 2003 August 13; 290 (6), 756]. JAMA, 289, 1645-1651.
128. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia:risks and benefits up to 9 years of treatment. [see comment] [erratum appears in JAMA 2003 August 13; 290 (6), 756]. JAMA, 289, 1645-1651.
129. Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F. & Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. [see Comment]. Blood, 91, 616-622.
130. Storen, E.C. & Tefferi, A. (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood, 97, 863-866.
131. Tartaglia, A.P., Goldberg, J.D., Berk, P.D. & Wasserman, L.R. (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Seminars in Hematology, 23, 172-176.
132. Tefferi, A. (2003) Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings, 78, 174-194.
133. Tefferi, A. & Murphy, S. (2001) Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Reviews, 15, 121-131.
134. Tefferi, A., Silverstein, M.N., Petitt, R.M., Mesa, R.A. & Solberg, Jr L.A., (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Seminars in Thrombosis and Hemostasis, 23, 379-383.
135. Tefferi, A., Mesa, R.A., Nagorney, D.M., Schroeder, G. & Silverstein, M.N. (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood, 95, 2226-2233.
136. Tefferi, A., Fonseca, R., Pereira, D.L. & Hoagland, H.C. (2001) A long-term retrospective study of young women with essential thrombocythemia. Mayo Clinical Proceedings, 76, 22-28.
137. Tsai, H.M. (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 4235-1244.
138. Turitto, V.T. & Weiss, H.J. (1983) Platelet and red cell involvement in mural thrombogenesis. Annals of the New York Academy of Sciences, 416, 363-376.
139. Ushikubi, F., Okuma, M., Ishibashi, T., Narumiya, S. & Uchino, H. (1990) Deficient elevation of the cytoplasmic calcium ion concentration by epinephrine in epinephrine-insensitive platelets of patients with myeloproliferative disorders. American Journal of Hematology, 33, 96-100.
140. Valla, D., Casadevall, N., Lacombe, C., Varet, B., Goldwasser, E., Franco, D., Maillard, J.N., Pariente, E.A., Leporrier, M. & Rueff, B. (1985) Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Annals of Internal Medicine, 103, 329-334.
141. Van Cott, E.M., Laposata, M. & Prins, M.H. (2002) Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Archives of Pathology and Laboratory Medicine, 126, 1281-1295.
142. Wade, J.P., Pearson, T.C., Russell, R.W. & Wetherley-Mein, G. (1981) Cerebral blood flow and blood viscosity in patients with polycythaemia secondary to hypoxic lung disease. British Medical Journal (Clinical Research Edition), 283, 689-692.
143. Warkentin, T.E., Roberts, R.S., Hirsh, J. & Kelton, K.G. (2003). An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine, 163, 2518-2524.
144. Watson, K.V. & Key, N. (1993) Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. British Journal of Haematology, 83, 198-203.
145. Waysbort, A., Giroux, M., Mansat, V., Teixeira, M., Dumas, J.C. & Puel, J. (1993) Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrobial Agents and Chemotherapy, 37, 1232-1237.
146. Wehmeier, A., Scharf, R.E., Fricke, S. & Schneider, W. (1989) Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis, 19, 251-259.
147. Wehmeier, A., Fricke, S., Scharf, R.E. & Schneider, W. (1990) A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. European Journal of Haematology, 45, 191-197.
148. Wehmeier, A., Daum, I., Jamin, H. & Schneider, W. (1991a) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Annals of Hematology, 63, 101-106.
149. Wehmeier, A., Tschope, D., Esser, J., Menzel, C., Nieuwenhuis, H.K. & Schneider, W. (1991b) Circulating activated platelets in myeloproliferative disorders. Thrombosis Research, 61, 271-278.
150. Weiss, H.J., Witte, L.D., Kaplan, K.L., Lages, B.A., Chernoff, A., Nossel, H.L., Goodman, D.S. & Baumgartner, H.R. (1979) Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood, 54, 1296-1319.
151. Willoughby, S. & Pearson, T.C. (1998) The use of aspirin in polycythaemia vera and primary thrombocythaemia. Blood Reviews, 12, 12-22.
152. Wu, K.K. (1978) Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Annals of Internal Medicine, 88, 7-11.